Anavex Life Sciences Corp (AVXL)

[crescentmotor]

What we are looking at is to likely a large extend a notoriously difficulty in measuring with any accuracy treatment effects in Rett as an indication without established objective biomarkers.

The only thing that makes sense to me is putting full stop on Rett until the AD situation firms up. It's fine to chit-chat with the regulators about things but no undertaking of expensive new Rett trials. AVXL's $146 million cash position does not provide a lot of attractive options and the hook is already set for advancing 3-71. Missling must choose wisely--he cannot just continue floating downstream wistfully waiting for a current to appear. The important unanswered question in my mind is if AVXL can move forward in AD and rope in a strong partner. Having to dilute the shareholders holding a sub $5 stock is a fool's errand. Right now Rett is dead in the water and should stay that way for a while--just my opinion.